Leap Therapeutics Inc

+0.21 (+9.05%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)244.63M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.31 Million
Adjusted EPS-$0.11
See more estimates
10-Day MA$2.36
50-Day MA$2.93
200-Day MA$2.09
See more pivots

Leap Therapeutics Inc Stock, NASDAQ:LPTX

47 Thorndike Street, Suite B1-1, Cambridge, Massachusetts 02141
United States of America
Phone: +1.617.714.0360
Number of Employees: 30


Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01, which is a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1 and TRX518, which is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.